Rhovica Neuroimaging AG (Rhovica), a Swiss medtech startup, has raised €2.5 million in a financing round led by M2care, with participation from Kickfund, Valuemaker, and several other business angels. The funding will accelerate the development of SoNav, Rhovica’s bedside navigation system for extraventricular drainage (EVD) catheters used in emergency neurosurgery.
“This fundraising marks an important milestone for Rhovica. The trust of our investors strengthens our ability to advance the development of SoNav and move closer to making this solution available to patients in need,” stated the CEO and Co-founder of Rhovica, Martin Hlavica.
Florence Thueux, President of M2care, commented:
“M2care combines investment capacity with hands-on expertise to de-risk early healthtech ventures to Series-A readiness. Rhovica reflects this approach: addressing a clear clinical need with a strong team and a technology that can transform emergency neurosurgery. We are proud to actively support the company in this next phase of development.”
Rhovica addresses a critical challenge in emergency neurosurgery: the safe and fast placement of life-saving EVD catheters to relieve increased intracranial pressure, for example, after severe trauma or intracranial bleeding. Today, neurosurgeons typically perform this emergency procedure blindly. Real-time visualization and navigation are not available directly at the bedside, increasing clinical risks. Rhovica’s SoNav system is designed to provide bedside real-time visualization and guidance to improve speed, accuracy and subsequent patient monitoring in intensive care. With this approach, the company positions itself in the growing neurosurgical device market environment, which is expected to grow between 4.5%1 and 14.2%2 in the coming years.
To further strengthen its development, Rhovica has appointed Carsten Laue, Managing Director at M2care, to its Board of Directors. His expertise in medtech strategy and company building will support the company in advancing SoNav™ toward clinical adoption.
Carsten Laue added: “By joining Rhovica’s board, I look forward to actively supporting the team in translating a strong clinical need into a viable medtech solution. The project’s origin in emergency neurosurgical care, combined with the founders’ complementary expertise, reflects precisely the type of innovation that M2care is set up to accelerate.”
This financing round was led by M2care, alongside Swiss investment firms Kickfund and Valuemaker, as well as several business angels. Together, they bring strong medtech expertise and networks that will support Rhovica in its next phase of development.
